In human plasma, Selank inhibited enkephalin-degrading enzymes, with higher specificity for carboxypeptidases and dicarboxypeptidases than bestatin, which mainly inhibited aminopeptidases and carboxypeptidases.
In plain wordsIn lab tests, Selank blocked enzymes in human plasma that break down enkephalin, acting on different enzyme types than bestatin.
- Peptide
- Selank
- Outcome
- DecreaseInhibition of enkephalin-degrading enzymes of human plasma
- Study
humann: not reported in source
human plasma- Comparator
- Bestatin
- Outcome group
- Receptor activity and mechanism · Pharmacology
- Studied dose
- Dose not stated
Source sentences
Bestatin was shown to predominantly inhibit aminopeptidases and carboxypeptidases, whereas Selank is more specific for carboxypeptidases and dicarboxypeptidases.
1 context sentence(design, population, supporting numbers)
[G-3H]Leu-enkephalin was prepared by the method of solid phase catalytic isotope exchange (120 Ci/mmol) and subjected to proteolysis by the treatment with blood plasma.